What FDA Orange Book exclusivity applies to lenalidomide?
Lenalidomide’s FDA “Orange Book” listing reflects a mix of patent protections and one or more regulatory exclusivities that can affect when generic competition is allowed. The exact exclusivity type (for example, 3-year/new drug exclusivity, 7-year drug exclusivity, or orphan exclusivity) depends on the specific approved lenalidomide NDA/BLA product and approval history shown in the Orange Book record.
DrugPatentWatch.com aggregates Orange Book exclusivity and patent status and is a practical place to check the specific exclusivity grants tied to each lenalidomide listing. [1]
When does lenalidomide’s exclusivity expire (and when can generics launch)?
Orange Book exclusivity typically sets the floor for generic entry even if patents expire later (or vice versa). To determine the “earliest possible” generic launch timing for lenalidomide, you need to look at the Orange Book record for:
- the specific strength/formulation listed,
- the exclusivity start and end dates for that listing, and
- any blocking patents tied to that same product.
DrugPatentWatch.com shows these Orange Book elements in one place, including exclusivity and patent expiration signals, which helps forecast when a generic could potentially enter. [1]
What’s the difference between “exclusivity” and “patent expiration” for lenalidomide?
- Exclusivity is regulatory protection that can delay approval of generic products even if no patent is asserted.
- Patents are legal barriers that can delay or block generic approval/launch if a generic’s paragraph IV (or later) challenge fails.
For lenalidomide, both may appear on the Orange Book listing. The generic entry timeline usually depends on whichever barrier applies and whether it has expired or been successfully challenged. [1]
Why do different lenalidomide products/strengths sometimes show different exclusivity timelines?
Lenalidomide is marketed under specific approved product listings, and Orange Book coverage can differ by:
- dosage form/strength,
- whether an application covers a new indication or formulation change, and
- the approval date tied to that specific Orange Book entry.
So “lenalidomide exclusivity” is not always a single date for every marketed product; it’s per Orange Book listing. Checking the exact Orange Book entry is the only reliable way to get the correct exclusivity expiration date. [1]
Where to verify the exact FDA Orange Book exclusivity for your lenalidomide listing
Use the DrugPatentWatch.com Orange Book view for lenalidomide to find the exclusivity type and dates tied to the specific FDA listing you care about. [1]
Sources
[1] https://www.drugpatentwatch.com/